GHIF Announcements

Apr 16, 2020

GHGHIF portfolio company Atomo Diagnostics Limited listed today on Australian Securities Exchange

Net proceeds to be used for expanded production of rapid test devices for COVID-19 testing

20 September 2018

GHIF Leads $10 Million Series B Financing for Alydia Health

Financing Will Support U.S. Pivotal Study of Device Designed to Provide a Safe, Natural, and Rapid Solution for Postpartum Hemorrhage

16 July 2018

GHIF Leads €16 Million Series B Financing for Univercells

Investment proceeds will support commercialization of the company’s breakthrough biologics manufacturing technology

4 January 2018

GHIF Leads €10 Million Series C Financing for Themis Bioscience

Proceeds will support the further development of the company’s chikungunya vaccine candidate, which recently reported encouraging interim Phase II study data

13 July 2017

GHIF and Visionary Venture Fund Back Iantech

Iantech will use the funding to further R&D and commercial efforts for its miLOOP technology, which has the potential to significantly improve global efforts to address cataract-induced visual impairment

31 January 2017

PATH, Clarus, and GHIF Announce $25 Million Anthelmintic Collaboration

Innovative financing arrangement will improve treatment of intestinal worms, affecting more than 1 billion people globally

21 December 2016

KfW Development Bank Publishes GHIF Project Update

Report indicates GHIF is performing against original impact investment objectives

30 March 2016

Access Bio Added to GHIF Portfolio as 6th Investment

$8 million of convertible note proceeds will finance the purchase and installation of new manufacturing equipment for Access Bio’s rapid diagnostic test products

13 January 2016

GHIF Makes $6 Million Loan to Atomo Diagnostics

The investment will support continued rollout of Atomo’s award-winning AtomoRapid™ HIV test and launch of an affordable HIV self-test offering unmatched performance

8 January 2016

GHIF-Backed EuBiologics Earns WHO Endorsement for Euvichol

WHO prequalification of Euvichol will double the availability of approved oral cholera vaccine in 2016

8 March 2015

$10 Million Investment into the Registration of Moxidectin, an Important New Global Health Medicine for River Blindness

If approved, moxidectin is expected to significantly accelerate the eradication of this terrible neglected disease

27 August 2014

GHIF Leads $7.5 Million Investment into Cholera Vaccine Manufacturer

Korean biopharmaceutical company commits to manufacture a new and improved presentation of the vaccine at a target price of $1.00 per dose for public sector buyers 

22 July 2014

GHIF Invests in Epistem to Finance New TB Diagnostic

Investment will support the roll-out of Epistem’s Genedrive® molecular diagnostic platform as the company’s tuberculosis assay enters pivotal field trials in key developing world locations

GHIF in the News

23 October 2018

Carl Zeiss Meditec to Acquire IanTECH, Inc. to expand its portfolio in cataract surgery

ZEISS to enhance its portfolio of Surgical Ophthalmology solutions, further positioning the Company as a global innovation leader and solution provider in the full space of ophthalmology.

22 July 2018

Australian not-for-profit wins unprecedented approval for blindness drug

An Australian company has won unprecedented US approval for a new drug to treat the second most common preventable cause of blindness in the world. In the process, Medicines Development for Global Health became the first not-for-profit company in the world to register a treatment with the US Food and Drug Administration.

7 March 2018

Global health coalition inks agreement to develop vaccines for MERS, Lassa fever

The Coalition for Epidemic Preparedness Innovations said this week that it has awarded its first contract, an agreement with an Austrian biotech company [GHIF-backed Themis Bioscience] to develop vaccines to protect against Middle East respiratory syndrome, or MERS, and Lassa fever.

17 January 2018

A new powerful drug to combat river blindness

Recently published phase 3 study results in The Lancet show that GHIF-backed moxidectin is a promising treatment for onchocerciasis, with the potential to “reduce parasite transmission between treatment rounds more than ivermectin could, thus accelerating progress towards elimination.”

10 January 2018

Oral cholera vaccine in lighter plastic packaging hits market

The International Vaccine Institute said Tuesday that the world’s first oral cholera vaccine packaged in plastic tube vials is now available for purchase. The vaccine, named Euvichol-Plus, was developed by South Korean drug-maker EuBiologics, with financing for the plastic tube program provided by the Global Health Investment Fund.

25 May 2017

This fund seeks a traditional return and grantlike impact for global health R&D

Staff at the Bill & Melinda Gates Foundation and J.P. Morgan said they hope the Global Health Investment Fund will demonstrate that it is possible to generate social impact, reduce costs to health care systems and deliver financial returns to investors at the same time.

13 December 2016 :: Barron’s Penta Daily

How to Make Money With Impact Investments

“Social-impact investing might often be about the intangible benefits provided to society. When it comes to your portfolio, however, you want to be sure the financial returns delivered aren’t intangible, but very real.”

29 November 2016 :: Inside Philanthropy

Can Investing in Rapid Self-Testing Disrupt the HIV/AIDS Mortality Curve?

Earlier this year, the Global Health Investment Fund (GHIF) announced that it was making a $6 million loan to Atomo Diagnostics, a point-of-care diagnostics company improving rapid testing platforms

5 October 2016 :: Bloomberg Radio

The Bloomberg Advantage: LaBelle on Social Impact on Medicine

Curt Labelle, Managing Partner at the Global Health Investment Fund, discussing working to save lives, while also lowering healthcare costs in the developing world

2 October 2013 :: Jamie Dimon

Innovating and Investing for Life-Saving Impact

GHIF will give individual and institutional investors their first ever opportunity to finance late-stage global health technologies that have the potential to save millions of lives in low-income countries

23 September 2013 :: The Globe and Mail

Billionaires team up to fight disease in developing world

Public-private partnerships are increasingly the norm when it comes to tackling vexing global health challenges

23 September 2013 :: JPMorgan Chase & Co.

New Investment Fund Will Advance Late-Stage Vaccines and other Global Health Technologies

JPMorgan Chase, the Bill & Melinda Gates Foundation and partners announce successful capital raise for first-of-its-kind investment product

@theGHIF Twitter Feed

GHIF Buzz on Twitter